BioSpace
by BioSpace
Latest episode
Stability, speed and strategy: Inside Australia’s early‑stage edge
Stability, speed and strategy: Inside Australia’s early‑stage edge
About this podcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Episodes
The newest 20 of 279 episodes
- Stability, speed and strategy: Inside Australia’s early‑stage edge · 21 minIn this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian…
- Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025 · 24 minMerck stole the show at the European Society for Medical Oncology (ESMO) annual conference, with new data on its Moderna-partnered personalized cancer vaccine leaking prior to…
- Why investors are taking another look at kidney disease · 18 minIn this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for…
- Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners · 18 minChina cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease…
- Bonus: Q3 2026 Job Market Update · 16 minBioSpace Vice President Chantal Dresner and Angela Gabriel, content manager, life sciences careers, cover what happened in the biopharma job market during the third quarter. They…
- The decisions behind scientific progress · 11 minIn this episode of Denatured, sponsored by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, we…
- J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback · 20 minJohnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1…
- Beyond equity: Why venture debt is reshaping European biotech · 23 minIn this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when…
- Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more · 24 minNew data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have…
- The race for access: How the FAIR Act could reclaim U.S. biotech leadership · 20 minIn this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are…
- AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll · 20 minSummit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its…
- How radioligand therapy is rewriting cancer care · 16 minIn this episode of Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America and Professor Sabine Brookman-May, vice president and head of…
- Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz · 21 minNovo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors are unconvinced it…
- When vision fades: Rethinking wet AMD and the durability gap · 22 minIn this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami Health System and Bascom Palmer Eye Institute, and Wesley…
- FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival · 22 minThe FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for reauthorizing the…
- The supply chain fault lines of modern pharma · 36 minIn this episode of Denatured, sponsored by SK Pharmteco, Jennifer Smith-Parker speaks to Arvind Singh, vice president and global head of supply chain. In this episode, we discuss…
- Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease · 20 minSeptember has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both…
- Breaking borders: Building biotech scale in Benelux · 19 minIn this episode of Denatured, you’ll listen to Christina Takke, managing partner at V-Bio Ventures and Mariette van der Velden-Roesink, founding partner at Curie Capital. We…
- Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals · 20 minNovartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA…
- Fragile X at a turning point: Breaking through the clinical bottleneck · 19 minIn this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA…
